scispace - formally typeset
L

Louise Neilson

Researcher at British American Tobacco

Publications -  12
Citations -  319

Louise Neilson is an academic researcher from British American Tobacco. The author has contributed to research in topics: Computer science & Medicine. The author has an hindex of 4, co-authored 8 publications receiving 224 citations.

Papers
More filters
Journal ArticleDOI

In silico toxicology protocols.

Glenn J. Myatt, +83 more
TL;DR: The publication presents a novel approach for determining the reliability of in silico predictions alongside experimental data and discusses how to determine the level of confidence in the assessment based on the relevance and reliability of the information.
Journal ArticleDOI

Development of an in vitro cytotoxicity model for aerosol exposure using 3D reconstructed human airway tissue; application for assessment of e-cigarette aerosol.

TL;DR: Applicability of the EpiAirway™ model and exposure system was demonstrated, showing little cytotoxicity from e-cigarette aerosol and different aerosol formulations when compared directly with reference cigarette smoke, over the same exposure time.
Journal ArticleDOI

Skin sensitization in silico protocol

TL;DR: Based on the relevance of the mechanisms and effects as well as the strengths and limitations of the experimental systems used to identify them, rules and principles are defined for deriving skin sensitization in silico assessments.
Journal ArticleDOI

Evaluation of flavourings potentially used in a heated tobacco product: Chemical analysis, in vitro mutagenicity, genotoxicity, cytotoxicity and in vitro tumour promoting activity.

TL;DR: The addition of flavourings to the Neostiks tested did not alter the chemical profile of THP emissions or change in vitro responses relative to the unflavoured Neostik, and levels of measured toxicants were similar in the flavoured and unflavours Neostika emissions.
Journal ArticleDOI

In silico approaches in carcinogenicity hazard assessment: Current status and future needs

TL;DR: The current status of in silico tools for the assessment of each KC is summarized and the data gaps that need to be addressed are identified before a comprehensive insilico carcinogenicity protocol can be developed for regulatory use.